The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of Alzheimer disease.
Jeffrey L. Cummings, MD, ScD
Advertisement
Articles by Jeffrey L. Cummings, MD, ScD
The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of agitation and psychosis in Alzheimer disease.
Advertisement
Latest Updated Articles
Jeffrey L. Cummings, MD, ScD: Addressing Agitation, Psychosis in Alzheimer DiseasePublished: July 28th 2019 | Updated:
- Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease
Published: August 13th 2019 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
2
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
3
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
4
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology
5
